News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

Voice of Industry: Sedia 2.x: Scaling up and overcoming challenges, Part 2

Oregon Bio recently caught up with Sedia Biosciences Corp.’s two founders, Roger Gale and Ron Mink, Ph.D. to learn more – not only about how its coping with Covid-19 impacts but more about the company’s innovation strategies. Last week we ran Part 1.

Recently, Sedia worked with the City of Beaverton to relocate to expand product manufacturing capabilities to serve an increasing demand for HIV diagnostic and epidemiological assays, specifically HIV recency diagnostics. Although the company started small […]

August 7, 2020 |

Post-DEI event: Discussions and takeaways

Last Thursday, Oregon Bio culled together about 100 industry pros for a Diversity Dialogue around equity and inclusion. Participants from a broad range of multi-cultural backgrounds and experiences engaged with panelists Emmanuel Akporiaye, Ph.D., founder of Veana Therapeutics; Ndongo “Don” Khouma, principal validation engineer at Genentech; and Nate Miles, vice president of Strategic Initiatives, State Government Affairs at Eli Lilly & Company. Soundharya Nagasubramanian, director of R&D in Product Information […]

August 4, 2020 |

Oregon Bio hosts free, virtual diversity dialogue to address racism and health disparities

On Thursday, July 30, BIPOC leaders and life science experts will convene for Diversity Dialogue: #BeTheChange. The panelists are respected bio professionals Dr. Emmanuel Akporiaye, founder of Veana Therapeutics; Ndongo Khouma, principal validation engineer at Genentech; and Nate Miles, vice president of Strategic Initiatives in State Government Affairs at Eli Lilly and Company.  Moderating the dialogue is Soundharya Nagasubramanian, director of R&D in Product Information Security at Hillrom/Welch Allyn.

“Diversity, inclusion and belonging are an important […]

Sedia Biosciences Corporation announces expansion and move to new research and manufacturing facility in Beaverton, Oregon, USA

Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide

Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon.  The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities.  Equipped with multiple state of […]

August 3, 2020 |

Voice of Industry: Sedia 2.x: Expansion, relocation and scaling up tracks growth, Part 1

Oregon Bio recently caught up with Sedia Biosciences Corp.’s founders Roger Gale and Ron Mink, Ph.D. to learn more about the company’s growth and innovation strategies.

Recently, Sedia worked with the City of Beaverton to relocate to expand product manufacturing capabilities to serve an increasing demand for HIV diagnostic and epidemiological assays, specifically HIV recency diagnostics. Although the company started small in Portland in 2009, just a decade later it now counts 40 employees (and growing), serving global […]

Local biotechnology company, Grace Bio-Labs, makes clinical grade hand sanitizer for area hospitals available to the public

Not all hand sanitizers are made the same; Efficacy is compromised in many cheaper brands

Local Bend based Biotechnology company, Grace Bio Labs, has been producing pharmaceutical grade hand sanitizer exclusively for St. Charles Hospitals since the beginning of the pandemic. Grace Bio Labs formula was developed as a clinical grade I product and is made from 70% isopropanol, meeting WHO recommended and CDC guidelines for effectiveness in killing most bacteria and many viruses, like Covid-19.

By pivoting their production during this […]

July 29, 2020 |

Oregon mentors needed in early August: National ICorps Bio-entrepreneur program for underrepresented early career researchers

WHO: Mentor early-career life science researchers from groups underrepresented in biotechnology research organizations. Participants include research-active assistant professors, postdoctoral fellows, graduate students and advanced undergraduates from universities and colleges nationwide.

WHY: • Promote diversity within Biotechnology in your region by engaging with underrepresented workshop participants
• Connect with participants in your region and provide ongoing resources
• Work with teams as they solve problems through entrepreneurial concepts
• Assist teams in developing a professional network and provide feedback as they execute customer discovery through BIO’s […]

July 27, 2020 |

Veana announces clinical collaboration with University of Washington for novel oral oncology candidate, Alpha-TEA in advanced HER2+ breast cancer

Phase I Study to Evaluate alpha-TEA in Combination With Trastuzumab (HerceptinTM) in Patients with Advanced HER2 Positive Breast Cancer
Portland, OR July 24, 2020

Veana Therapeutics Inc. is pleased to announce that it has entered into a clinical research collaboration with the University of Washington to conduct a Phase I clinical trial of its lead agent, alpha-TEA (aka a-TEA lysine) in combination with trastuzumab (HerceptinTM) in HER2+ breast cancer patients. a-TEA lysine salt is a novel, first-in-class small molecule that destabilizes mitochondria […]

Alpha Cancer technologies to license AbSci’s SoluPro strain for the expression of alpha-fetoprotein

VANCOUVER, Wash., July 21, 2020 /PRNewswire/ — AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E. coli SoluPro® protein expression technology to Alpha Cancer Technologies for the production of Recombinant Human Alpha-fetoprotein (hAFP). hAFP is a natural human protein produced by human embryo and yolk sac during development and can be used in the treatment of various autoimmune diseases and cancers.  This license is […]

July 24, 2020 |